DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $39,103,041 | +1.3% | 157,610 | -2.0% | 1.09% | +6.3% |
Q2 2023 | $38,604,240 | -15.6% | 160,851 | -11.4% | 1.03% | -16.8% |
Q1 2023 | $45,755,846 | -6.7% | 181,542 | -1.8% | 1.24% | -6.2% |
Q4 2022 | $49,043,246 | +2.0% | 184,776 | -0.8% | 1.32% | -3.4% |
Q3 2022 | $48,092,000 | +1.1% | 186,192 | -0.7% | 1.36% | +5.8% |
Q2 2022 | $47,555,000 | -15.6% | 187,580 | -2.4% | 1.29% | -0.5% |
Q1 2022 | $56,364,000 | -10.3% | 192,153 | +0.6% | 1.30% | +1.8% |
Q4 2021 | $62,831,000 | +7.3% | 190,970 | -0.7% | 1.27% | -0.4% |
Q3 2021 | $58,530,000 | +7.4% | 192,254 | -5.3% | 1.28% | +3.9% |
Q2 2021 | $54,479,000 | +19.7% | 203,009 | +0.4% | 1.23% | +15.0% |
Q1 2021 | $45,528,000 | +7.8% | 202,276 | +6.4% | 1.07% | -1.0% |
Q4 2020 | $42,228,000 | -5.6% | 190,098 | -8.5% | 1.08% | -18.5% |
Q3 2020 | $44,713,000 | +18.7% | 207,649 | -2.5% | 1.32% | +10.6% |
Q2 2020 | $37,662,000 | +30.6% | 212,982 | +2.2% | 1.20% | +17.6% |
Q1 2020 | $28,835,000 | -15.1% | 208,332 | -5.8% | 1.02% | +5.8% |
Q4 2019 | $33,958,000 | +7.5% | 221,256 | +1.1% | 0.96% | -0.3% |
Q3 2019 | $31,602,000 | +2.0% | 218,804 | +0.9% | 0.97% | +0.9% |
Q2 2019 | $30,990,000 | +8.2% | 216,837 | -0.1% | 0.96% | +4.1% |
Q1 2019 | $28,641,000 | +30.7% | 216,947 | +2.1% | 0.92% | +14.4% |
Q4 2018 | $21,911,000 | -5.4% | 212,476 | -0.4% | 0.80% | +25.5% |
Q3 2018 | $23,169,000 | +11.1% | 213,227 | +0.9% | 0.64% | +6.1% |
Q2 2018 | $20,859,000 | +1.0% | 211,384 | +0.3% | 0.60% | -13.7% |
Q1 2018 | $20,643,000 | +6.6% | 210,841 | +1.1% | 0.70% | +6.6% |
Q4 2017 | $19,361,000 | +7.2% | 208,589 | -0.9% | 0.66% | +2.0% |
Q3 2017 | $18,061,000 | +1.2% | 210,546 | -0.5% | 0.64% | -3.9% |
Q2 2017 | $17,854,000 | +11.8% | 211,569 | +13.3% | 0.67% | +9.5% |
Q1 2017 | $15,966,000 | +14.2% | 186,675 | +4.0% | 0.61% | +16.4% |
Q4 2016 | $13,977,000 | +5.8% | 179,557 | +6.5% | 0.52% | +11.7% |
Q3 2016 | $13,212,000 | +3.5% | 168,548 | +33.3% | 0.47% | +1.5% |
Q2 2016 | $12,770,000 | +9.2% | 126,438 | +2.5% | 0.46% | +20.9% |
Q1 2016 | $11,696,000 | -23.7% | 123,296 | -25.3% | 0.38% | -23.1% |
Q4 2015 | $15,338,000 | +32.3% | 165,134 | +21.4% | 0.50% | +45.6% |
Q3 2015 | $11,591,000 | -2.1% | 136,034 | -1.7% | 0.34% | +13.6% |
Q2 2015 | $11,842,000 | +2.0% | 138,359 | +1.2% | 0.30% | +3.1% |
Q1 2015 | $11,613,000 | -1.6% | 136,779 | -0.6% | 0.29% | +2.1% |
Q4 2014 | $11,798,000 | +13.4% | 137,654 | +0.5% | 0.29% | +8.7% |
Q3 2014 | $10,405,000 | -3.6% | 136,944 | -0.1% | 0.26% | +0.8% |
Q2 2014 | $10,796,000 | +7.8% | 137,124 | +2.7% | 0.26% | +6.5% |
Q1 2014 | $10,011,000 | -0.6% | 133,479 | +2.3% | 0.24% | -6.5% |
Q4 2013 | $10,069,000 | +20.6% | 130,429 | +8.3% | 0.26% | +15.4% |
Q3 2013 | $8,348,000 | +8.7% | 120,430 | -0.8% | 0.23% | +2.7% |
Q2 2013 | $7,683,000 | +8.7% | 121,370 | +6.7% | 0.22% | +0.9% |
Q1 2013 | $7,069,000 | +90.6% | 113,735 | +71.4% | 0.22% | +81.0% |
Q4 2012 | $3,709,000 | – | 66,350 | – | 0.12% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |